KR102466794B1 - 상처 치료 방법 - Google Patents

상처 치료 방법 Download PDF

Info

Publication number
KR102466794B1
KR102466794B1 KR1020227026917A KR20227026917A KR102466794B1 KR 102466794 B1 KR102466794 B1 KR 102466794B1 KR 1020227026917 A KR1020227026917 A KR 1020227026917A KR 20227026917 A KR20227026917 A KR 20227026917A KR 102466794 B1 KR102466794 B1 KR 102466794B1
Authority
KR
South Korea
Prior art keywords
antibody
wound
seq
vegf
ser
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020227026917A
Other languages
English (en)
Korean (ko)
Other versions
KR20220115815A (ko
Inventor
울프 에릭슨
아넬리 팔케발
아니카 멜렘
Original Assignee
씨에스엘 리미티드
비-크리에이티브 스웨덴 아베
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2013904942A external-priority patent/AU2013904942A0/en
Application filed by 씨에스엘 리미티드, 비-크리에이티브 스웨덴 아베 filed Critical 씨에스엘 리미티드
Publication of KR20220115815A publication Critical patent/KR20220115815A/ko
Application granted granted Critical
Publication of KR102466794B1 publication Critical patent/KR102466794B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/00113—Growth factors
    • A61K39/001135—Vascular endothelial growth factor [VEGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Oncology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020227026917A 2013-12-18 2014-12-18 상처 치료 방법 Active KR102466794B1 (ko)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
AU2013904942A AU2013904942A0 (en) 2013-12-18 Method of treating wounds
AU2013904942 2013-12-18
AU2013904966 2013-12-19
AU2013904966A AU2013904966A0 (en) 2013-12-19 Method of treating wounds
PCT/AU2014/050431 WO2015089585A1 (en) 2013-12-18 2014-12-18 Method of treating wounds
KR1020167019187A KR20160096194A (ko) 2013-12-18 2014-12-18 상처 치료 방법

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020167019187A Division KR20160096194A (ko) 2013-12-18 2014-12-18 상처 치료 방법

Publications (2)

Publication Number Publication Date
KR20220115815A KR20220115815A (ko) 2022-08-18
KR102466794B1 true KR102466794B1 (ko) 2022-11-11

Family

ID=53401804

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020227026917A Active KR102466794B1 (ko) 2013-12-18 2014-12-18 상처 치료 방법
KR1020167019187A Ceased KR20160096194A (ko) 2013-12-18 2014-12-18 상처 치료 방법

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020167019187A Ceased KR20160096194A (ko) 2013-12-18 2014-12-18 상처 치료 방법

Country Status (13)

Country Link
US (1) US10543270B2 (cg-RX-API-DMAC7.html)
EP (1) EP3082860B1 (cg-RX-API-DMAC7.html)
JP (1) JP6553618B2 (cg-RX-API-DMAC7.html)
KR (2) KR102466794B1 (cg-RX-API-DMAC7.html)
CN (1) CN105979965B (cg-RX-API-DMAC7.html)
AU (1) AU2014366837B2 (cg-RX-API-DMAC7.html)
BR (1) BR112016014099A2 (cg-RX-API-DMAC7.html)
CA (1) CA2932465C (cg-RX-API-DMAC7.html)
DK (1) DK3082860T3 (cg-RX-API-DMAC7.html)
ES (1) ES2851386T3 (cg-RX-API-DMAC7.html)
PL (1) PL3082860T3 (cg-RX-API-DMAC7.html)
RU (1) RU2672377C1 (cg-RX-API-DMAC7.html)
WO (1) WO2015089585A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2881303T3 (es) 2014-11-17 2021-11-29 Csl Ltd Método para el tratamiento o prevención del accidente cerebrovascular
BR112018071467A2 (pt) * 2016-04-21 2019-02-05 Csl Limited método de tratamento ou prevenção de patologias hepáticas
WO2023115112A1 (en) * 2021-12-20 2023-06-29 CSL Innovation Pty Ltd Protein formulations and uses thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126698A2 (en) 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters

Family Cites Families (60)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5807715A (en) 1984-08-27 1998-09-15 The Board Of Trustees Of The Leland Stanford Junior University Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US5618920A (en) 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US5260203A (en) 1986-09-02 1993-11-09 Enzon, Inc. Single polypeptide chain binding molecules
ATE102631T1 (de) 1988-11-11 1994-03-15 Medical Res Council Klonierung von immunglobulin sequenzen aus den variabelen domaenen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
WO1994004679A1 (en) 1991-06-14 1994-03-03 Genentech, Inc. Method for making humanized antibodies
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
WO1993011236A1 (en) 1991-12-02 1993-06-10 Medical Research Council Production of anti-self antibodies from antibody segment repertoires and displayed on phage
PT1589107E (pt) 1992-08-21 2010-03-29 Univ Bruxelles Imunoglobulinas desprovidas de cadeias leves
US20080152586A1 (en) 1992-09-25 2008-06-26 Avipep Pty Limited High avidity polyvalent and polyspecific reagents
EP1550729B1 (en) 1992-09-25 2009-05-27 Avipep Pty Limited Target binding polypeptide comprising an IG-like VL domain linked to an IG-like VH domain
EP0627932B1 (en) 1992-11-04 2002-05-08 City Of Hope Antibody construct
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
US5928939A (en) * 1995-03-01 1999-07-27 Ludwig Institute For Cancer Research Vascular endothelial growth factor-b and dna coding therefor
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US6113898A (en) 1995-06-07 2000-09-05 Idec Pharmaceuticals Corporation Human B7.1-specific primatized antibodies and transfectomas expressing said antibodies
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US6699658B1 (en) 1996-05-31 2004-03-02 Board Of Trustees Of The University Of Illinois Yeast cell surface display of proteins and uses thereof
AU740043B2 (en) 1996-06-27 2001-10-25 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw Recognition molecules interacting specifically with the active site or cleft of a target molecule
DE19742706B4 (de) 1997-09-26 2013-07-25 Pieris Proteolab Ag Lipocalinmuteine
US6506559B1 (en) 1997-12-23 2003-01-14 Carnegie Institute Of Washington Genetic inhibition by double-stranded RNA
AUPP221098A0 (en) 1998-03-06 1998-04-02 Diatech Pty Ltd V-like domain binding molecules
CA2323726C (en) 1998-03-20 2005-02-08 Benitec Australia Ltd. Control of gene expression
DK1068311T3 (da) 1998-04-08 2011-08-08 Commw Scient Ind Res Org Fremgangsmåder og midler til opnåelse af modificerede fænotyper
ATE352559T1 (de) 1998-12-08 2007-02-15 Biovation Ltd Verfahren zur verminderung der immunogenität von proteinen
US7115396B2 (en) 1998-12-10 2006-10-03 Compound Therapeutics, Inc. Protein scaffolds for antibody mimics and other binding proteins
US7270969B2 (en) 1999-05-05 2007-09-18 Phylogica Limited Methods of constructing and screening diverse expression libraries
US6326193B1 (en) 1999-11-05 2001-12-04 Cambria Biosciences, Llc Insect control agent
AU2002218166A1 (en) 2000-09-08 2002-03-22 Universitat Zurich Collections of repeat proteins comprising repeat modules
WO2002088171A2 (en) 2001-04-26 2002-11-07 Avidia Research Institute Combinatorial libraries of monomer domains
CN1671416B (zh) 2001-07-12 2013-01-02 杰斐逊·富特 超人源化抗体
DE60310383T2 (de) * 2002-01-29 2007-09-20 Vlaams Interuniversitair Instituut Voor Biotechnologie Vzw. Vorbeugung von gewebeadhäsion
CA2429483A1 (en) 2002-05-17 2003-11-17 Amrad Operations Pty Ltd. Immunointeractive molecules
US20030232439A1 (en) 2002-06-17 2003-12-18 Isis Pharmaceuticals Inc. Antisense modulation of VEGF-B expression
US7217798B2 (en) 2003-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of Fc-fusion protein serum half-lives by mutagenesis
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
CA2512729C (en) 2003-01-09 2014-09-16 Macrogenics, Inc. Identification and engineering of antibodies with variant fc regions and methods of using same
CN1822857A (zh) 2003-06-02 2006-08-23 阿莱克申药物公司 去免疫原性抗cd3抗体
ATE416190T1 (de) 2003-07-04 2008-12-15 Affibody Ab Polypeptide mit bindungsaffinität für her2
AU2003275958A1 (en) 2003-08-25 2005-03-10 Pieris Proteolab Ag Muteins of tear lipocalin
BRPI0417302A (pt) 2003-12-05 2007-03-06 Compound Therapeutics Inc inibidores de receptores de fator de crescimento endotelial vascular do tipo 2
US20050282233A1 (en) * 2004-03-05 2005-12-22 Ludwig Institute For Cancer Research Multivalent antibody materials and methods for VEGF/PDGF family of growth factors
DK1751181T3 (da) 2004-06-02 2012-11-26 Adalta Pty Ltd BINDINGSDELE, DER ER BASERET PÅ HAJ IgNAR-DOMÆNER
ES2456943T3 (es) 2004-08-02 2014-04-24 Zenyth Operations Pty. Ltd. Método de tratamiento de cáncer que comprende un antagonista de VEGF-B
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
AU2006281980A1 (en) 2005-08-15 2007-02-22 Cephalon Australia Pty Ltd Engineered antibodies with new world primate framework regions
WO2007140534A1 (en) * 2006-06-08 2007-12-13 Csl Limited Vegf-a cross-reactive anti- vegf-b antibodies as antagonists of vegf-a and vegf-b signalling
NZ579107A (en) * 2007-02-19 2012-05-25 Marinepolymer Tech Inc Poly-beta-1-4-n-acetylglucosamine hemostatic compositions and therapeutic regimens
WO2009045356A2 (en) * 2007-09-28 2009-04-09 Yale University Microrna compositions in the treatment of vegf-mediated disorders
CN102076844B (zh) * 2008-06-30 2013-08-07 成血管细胞系统公司 采用组合疗法的眼病和过度血管新生的治疗
RU2395521C1 (ru) * 2008-11-10 2010-07-27 Учреждение Российской Академии Наук Институт Биологии Гена Ран Наноантитело v9, связывающее vegf, и способ его получения, кодирующая v9 нуклеотидная последовательность и содержащий ее вектор, способ ингибирования пролиферации эндотелиальных клеток
MX348166B (es) 2008-12-19 2017-06-01 Macrogenics Inc Diacuerpos covalentes y sus usos.
US9259507B2 (en) * 2009-04-21 2016-02-16 Warsaw Orthopedic, Inc. Tissue augmentation with active agent for wound healing
EP2367000A1 (en) 2010-03-04 2011-09-21 Charité Universitätsmedizin Berlin High throughput analysis of T-cell receptor repertoires

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009126698A2 (en) 2008-04-09 2009-10-15 Ludwig Institute For Cancer Research Regulation of fatty acid transporters

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Plastic and Reconstructive Surgery, 제132권, 제4호, 996-1004면(2013.10.)

Also Published As

Publication number Publication date
EP3082860A4 (en) 2017-08-16
EP3082860B1 (en) 2020-11-25
BR112016014099A2 (pt) 2017-10-10
PL3082860T3 (pl) 2021-06-14
CA2932465A1 (en) 2015-06-25
RU2672377C1 (ru) 2018-11-14
WO2015089585A1 (en) 2015-06-25
CN105979965A (zh) 2016-09-28
EP3082860A1 (en) 2016-10-26
AU2014366837B2 (en) 2020-06-25
KR20220115815A (ko) 2022-08-18
KR20160096194A (ko) 2016-08-12
CA2932465C (en) 2023-08-22
US20160319008A1 (en) 2016-11-03
ES2851386T3 (es) 2021-09-06
JP6553618B2 (ja) 2019-07-31
DK3082860T3 (da) 2021-01-25
JP2017501182A (ja) 2017-01-12
CN105979965B (zh) 2021-07-09
AU2014366837A1 (en) 2016-06-16
US10543270B2 (en) 2020-01-28
RU2016127196A (ru) 2018-01-23

Similar Documents

Publication Publication Date Title
KR102513989B1 (ko) 간 질환을 치료하거나 예방하는 방법
US10961304B2 (en) Method of reducing the effect of a stroke comprising administering an inhibitor of vascular endothelial growth factor B (VEGF-B)
JP6802342B2 (ja) 腎症を処置する方法
KR102466794B1 (ko) 상처 치료 방법
WO2024249444A2 (en) Wnt surrogate agents and methods for lacrimal gland regeneration
HK1228748B (en) Method of treating wounds
HK1242603B (en) Method of treating or preventing stroke
HK1228745B (en) Method of treating diabetic nephropathy
HK1228745A1 (en) Method of treating diabetic nephropathy

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20220803

Application number text: 1020167019187

Filing date: 20160715

PA0201 Request for examination
PG1501 Laying open of application
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220906

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221109

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221109

End annual number: 3

Start annual number: 1

PG1601 Publication of registration